GB2428240A - Diagnostic method for brain damage-related disorders - Google Patents

Diagnostic method for brain damage-related disorders Download PDF

Info

Publication number
GB2428240A
GB2428240A GB0514435A GB0514435A GB2428240A GB 2428240 A GB2428240 A GB 2428240A GB 0514435 A GB0514435 A GB 0514435A GB 0514435 A GB0514435 A GB 0514435A GB 2428240 A GB2428240 A GB 2428240A
Authority
GB
United Kingdom
Prior art keywords
protein
polypeptide
brain damage
alpha
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB0514435A
Other languages
English (en)
Other versions
GB0514435D0 (en
Inventor
Jean-Charles Sanchez
Denis Francois Hochstrasser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GEN VE, University of
Original Assignee
GEN VE, University of
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GEN VE, University of filed Critical GEN VE, University of
Priority to GB0514435A priority Critical patent/GB2428240A/en
Publication of GB0514435D0 publication Critical patent/GB0514435D0/en
Priority to AT06765356T priority patent/ATE456055T1/de
Priority to EP06765356A priority patent/EP1902319B1/en
Priority to PCT/GB2006/050207 priority patent/WO2007007129A2/en
Priority to AU2006268034A priority patent/AU2006268034B2/en
Priority to DE602006011896T priority patent/DE602006011896D1/de
Priority to CA2613991A priority patent/CA2613991C/en
Priority to ES06765356T priority patent/ES2336946T3/es
Priority to US11/995,501 priority patent/US9028825B2/en
Priority to JP2008520966A priority patent/JP5281397B2/ja
Publication of GB2428240A publication Critical patent/GB2428240A/en
Priority to JP2013011339A priority patent/JP2013092538A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
GB0514435A 2005-07-14 2005-07-14 Diagnostic method for brain damage-related disorders Withdrawn GB2428240A (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
GB0514435A GB2428240A (en) 2005-07-14 2005-07-14 Diagnostic method for brain damage-related disorders
JP2008520966A JP5281397B2 (ja) 2005-07-14 2006-07-14 脳損傷関連障害の診断法
AU2006268034A AU2006268034B2 (en) 2005-07-14 2006-07-14 Diagnostic method for brain damage-related disorders
EP06765356A EP1902319B1 (en) 2005-07-14 2006-07-14 Diagnostic method for brain damage-related disorders
PCT/GB2006/050207 WO2007007129A2 (en) 2005-07-14 2006-07-14 Diagnostic method for brain damage-related disorders
AT06765356T ATE456055T1 (de) 2005-07-14 2006-07-14 Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden
DE602006011896T DE602006011896D1 (de) 2005-07-14 2006-07-14 Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden
CA2613991A CA2613991C (en) 2005-07-14 2006-07-14 Diagnostic method for brain damage-related disorders
ES06765356T ES2336946T3 (es) 2005-07-14 2006-07-14 Metodo de diagnostico para trastornos relacionados con daño cerebral.
US11/995,501 US9028825B2 (en) 2005-07-14 2006-07-14 Diagnostic method for brain damage-related disorders
JP2013011339A JP2013092538A (ja) 2005-07-14 2013-01-24 脳損傷関連障害の診断法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0514435A GB2428240A (en) 2005-07-14 2005-07-14 Diagnostic method for brain damage-related disorders

Publications (2)

Publication Number Publication Date
GB0514435D0 GB0514435D0 (en) 2005-08-17
GB2428240A true GB2428240A (en) 2007-01-24

Family

ID=34897198

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0514435A Withdrawn GB2428240A (en) 2005-07-14 2005-07-14 Diagnostic method for brain damage-related disorders

Country Status (10)

Country Link
US (1) US9028825B2 (https=)
EP (1) EP1902319B1 (https=)
JP (2) JP5281397B2 (https=)
AT (1) ATE456055T1 (https=)
AU (1) AU2006268034B2 (https=)
CA (1) CA2613991C (https=)
DE (1) DE602006011896D1 (https=)
ES (1) ES2336946T3 (https=)
GB (1) GB2428240A (https=)
WO (1) WO2007007129A2 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9929140D0 (en) * 1999-12-10 2000-02-02 Univ Geneve Diagnostic assay for stroke
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
PL2021792T3 (pl) 2006-05-09 2013-08-30 Univ British Columbia Rozpuszczone białkowe markery zapalenia stawów
DE102006048201A1 (de) * 2006-10-11 2008-04-17 Ganymed Pharmaceuticals Ag Autoantigene zur verbesserten Diagnose, Prognose und Therapie von entzündlichen neurologischen Erkrankungen
WO2009036336A2 (en) * 2007-09-12 2009-03-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomarkers for motor neuron disease
JP5615181B2 (ja) 2007-11-27 2014-10-29 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 関節炎の予防及び治療のための組成物及び方法
MX340916B (es) 2008-01-18 2016-07-29 President And Fellows Of Harvard College * Metodos para detectar señales de identificacion de enfermedad o condiciones en fluidos corporales.
CA2725548A1 (en) * 2008-05-09 2009-11-12 Duke University Autoantibodies in the detection and treatment of cancer
JP5781436B2 (ja) 2008-08-11 2015-09-24 バンヤン・バイオマーカーズ・インコーポレーテッド 神経学的状態のバイオマーカー検出方法およびアッセイ
US12601749B2 (en) 2008-08-11 2026-04-14 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
US20120071337A1 (en) * 2009-01-26 2012-03-22 Electrophoretics Limited Methods
CA2751090A1 (en) * 2009-01-30 2010-08-05 Electrophoretics Limited Method for the in vitro diagnosis of stroke
WO2010102412A1 (en) 2009-03-11 2010-09-16 Augurex Life Sciences Corporation Compositions and methods for characterizing arthritic conditions
CA2807645C (en) 2009-08-07 2021-09-07 Affinimark Technologies, Inc. Device and methods for the immunological identification of cerebrospinal fluid
AU2010291933B2 (en) * 2009-09-14 2016-09-08 Banyan Biomarkers, Inc. Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury
RU2422095C1 (ru) * 2009-12-11 2011-06-27 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи" Способ прогнозирования эффективности местной химиотерапии при лечении больных злокачественными опухолями головного мозга
WO2011106322A2 (en) * 2010-02-23 2011-09-01 The Govt. Of The U.S.A. As Represented By The Secretary, Department Of Health And Human Services. Biomarkers for acute ischemic stroke
GB201008541D0 (en) * 2010-05-21 2010-07-07 Univ Geneve Diagnostic methods
EP2596132A4 (en) 2010-07-23 2013-12-18 Harvard College METHOD FOR DETECTING SIGNS FOR ILLNESS OR SUFFERING IN BODY FLUIDS
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
TW201209171A (en) 2010-07-23 2012-03-01 Harvard College Methods of detecting diseases or conditions using phagocytic cells
US20130203624A1 (en) 2010-07-23 2013-08-08 President And Fellows Of Harvard College Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions
WO2012051519A2 (en) * 2010-10-14 2012-04-19 The Johns Hopkins University Biomarkers of brain injury
JP6074846B2 (ja) 2010-12-16 2017-02-08 国立研究開発法人産業技術総合研究所 髄液型糖タンパク質の富化及び分離方法、並びにその方法を用いた中枢神経系疾患用マーカーの探索方法及び中枢神経系疾患用マーカー
WO2012152970A1 (es) * 2011-05-06 2012-11-15 Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol Método de diagnóstico del ictus isquémico
US20140141458A1 (en) 2011-05-12 2014-05-22 The Johns Hopkins University Assay reagents for a neurogranin diagnostic kit
US9792548B2 (en) 2011-09-22 2017-10-17 Bio-Rad Laboratories, Inc. Systems and methods for biochemical data analysis
PT2768851T (pt) 2011-10-21 2017-09-08 Augurex Life Sciences Corp Antigénios derivados de 14-3-3 citrulinada e utilizações dos mesmos no diagnóstico de artrite reumatoide
US20140370531A1 (en) * 2011-12-14 2014-12-18 University Of Rochester Method of diagnosing mild traumatic brain injury
HK1206425A1 (en) 2012-03-13 2016-01-08 The Johns Hopkins University Citrullinated brain and neurological proteins as biomarkers of brain injury or neurodegeneration
WO2013163345A1 (en) * 2012-04-24 2013-10-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of stroke or other cerebral injury
MX2014015434A (es) 2012-06-15 2015-07-14 Harry Stylli Metodos para detectar enfermedades o condiciones utilizando celulas enfermas en circulacion.
JP2015522260A (ja) 2012-06-15 2015-08-06 ハリー スティリ， 疾患または状態を検出する方法
NZ771629A (en) 2013-03-09 2022-12-23 Harry Stylli Methods of detecting cancer
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
SG11201510701QA (en) * 2013-06-28 2016-01-28 Mcbi Inc Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
US10534003B2 (en) 2013-07-17 2020-01-14 The Johns Hopkins University Multi-protein biomarker assay for brain injury detection and outcome
US10626464B2 (en) 2014-09-11 2020-04-21 Cell Mdx, Llc Methods of detecting prostate cancer
FI20155280A7 (fi) 2015-04-15 2016-10-16 Medicortex Finland Oy Aivovamman prognostisia ja diagnostisia glykaanipohjaisia biomarkkereita
CN105506083B (zh) * 2015-12-24 2018-10-19 孙梅芬 Capg在制备诊断帕金森症产品中的用途
JP6947451B2 (ja) * 2016-06-29 2021-10-13 学校法人自治医科大学 バイオマーカー、診断用組成物、及び診断用キット
WO2018002362A1 (en) * 2016-06-30 2018-01-04 Randox Laboratories Ltd Measurement of fabp for diagnosis
AU2017306558B2 (en) 2016-08-03 2024-09-19 University Of South Florida Reelin compositions for treatment of neurological disorders
CN109791139A (zh) * 2016-08-09 2019-05-21 大塚制药株式会社 使用尿液生物标记的阿兹海默氏症的辅助诊断方法
US10914748B2 (en) 2016-09-08 2021-02-09 UNIVERSITé LAVAL Erythrocyte-derived extracellular vesicles as a biomarker for clinically assessing Parkinson's disease
IL265195B2 (en) * 2016-09-16 2025-02-01 Dyax Corp Protein biomarkers for diseases related to the activation system
US11078298B2 (en) 2016-10-28 2021-08-03 Banyan Biomarkers, Inc. Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods
KR102466369B1 (ko) * 2020-08-04 2022-11-14 서울대학교병원 자가면역 뇌염의 진단 방법
JP7569552B2 (ja) * 2021-01-29 2024-10-18 国立大学法人東北大学 認知症診断用のバイオマーカー
CN114966045A (zh) * 2022-05-07 2022-08-30 浙江大学 检测抗肌球蛋白轻链1-IgG自身抗体的试剂在制备检测血管内皮损伤的试剂盒中的应用
CN115166260B (zh) * 2022-07-11 2023-06-13 东南大学 血浆脑细胞来源外泌体中维生素d结合蛋白在诊断抑郁症中的应用
CN118624905B (zh) * 2023-07-31 2025-04-01 中国人民解放军总医院第一医学中心 一种糖尿病性肾病诊断的生物标志物和试剂盒及诊断设备
CN120820725B (zh) * 2025-09-17 2026-01-27 上海交通大学医学院附属仁济医院 胶质纤维酸性蛋白和乳酸脱氢酶a亚型在制备诊断颅脑创伤的试剂盒中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048723A2 (en) * 1996-06-17 1997-12-24 MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. Hofgartenstrasse 2 Ptp-20, pcp-2, bdp1, clk and sirp proteins and related products
US20030054415A1 (en) * 1999-11-30 2003-03-20 Hans-Jorg Buhring Antibodies directed against signal regulator proteins
US20030109002A1 (en) * 1996-11-15 2003-06-12 Max-Planck-Gesellschaft Zur Foderung Der Wissenschaften E.V. SIRP proteins and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017A (en) * 1845-05-01 Reid r
US3015A (en) * 1843-03-21 Improvement in gilding, silvering
GB225245A (en) * 1923-11-23 1924-12-24 British Thomson Houston Co Ltd Improvements in and relating to elastic fluid turbines
GB322063A (en) * 1928-10-29 1929-11-28 Godwin Stanley Oliver Improvements relating to automatic vehicle-controlled track-signalling devices
JPH09110713A (ja) * 1995-10-13 1997-04-28 Nippon Green Ueebu Kk グルタチオン−ｓ−トランスフェラーゼ活性化剤並びにそれを含む医薬品及び飲食物
CA2263063C (en) * 1999-02-26 2004-08-10 Skye Pharmatech Incorporated Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
GB9929140D0 (en) 1999-12-10 2000-02-02 Univ Geneve Diagnostic assay for stroke
WO2001067108A2 (en) 2000-03-10 2001-09-13 Universite De Geneve Diagnostic assay for transmissible spongiform encephalopathies
GB2360089A (en) * 2000-03-10 2001-09-12 Univ Geneve Diagnostic assay for transmisible spongiform encephalopathies
US7608406B2 (en) * 2001-08-20 2009-10-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
AU2003274368B2 (en) 2002-10-30 2008-11-20 Proteome Sciences Plc. Diagnostic method for transmissible spongiform encephalopathies (prion diseases)
DK2341350T3 (en) * 2003-09-20 2018-02-05 Electrophoretics Ltd DIAGNOSTIC PROCEDURE FOR BRAKE INJURY-RELATED DISORDERS BASED ON DJ-1 DETECTION
US20050164238A1 (en) * 2003-09-29 2005-07-28 Biosite, Inc. Methods and compositions for the diagnosis of sepsis
GB0419124D0 (en) 2004-08-27 2004-09-29 Proteome Sciences Plc Methods and compositions relating to Alzheimer's disease
GB0421639D0 (en) 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
CA2590781A1 (en) 2004-12-07 2006-06-15 Electrophoretics Limited Diagnosis of neurodegenerative diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048723A2 (en) * 1996-06-17 1997-12-24 MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. Hofgartenstrasse 2 Ptp-20, pcp-2, bdp1, clk and sirp proteins and related products
US20030109002A1 (en) * 1996-11-15 2003-06-12 Max-Planck-Gesellschaft Zur Foderung Der Wissenschaften E.V. SIRP proteins and uses thereof
US20030054415A1 (en) * 1999-11-30 2003-03-20 Hans-Jorg Buhring Antibodies directed against signal regulator proteins

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J Immunol; Vol 161, pp 1853-1859 (1998). Adams et al. "Signal-regulatory protein is selectively expressed by myeloid and neuronal cells" *
J Neurovirol; Vol 9 (suppl 3), pg 82 (2003). Sulkowski et al. "SIRP signalling modulates neuronal Akt" *
Nature; Vol 386, pp 181-186 (1997). Kharitonenkov et al. "A family of proteins that inhibit signalling through tyrosine kinase receptors" *

Also Published As

Publication number Publication date
WO2007007129A2 (en) 2007-01-18
ES2336946T3 (es) 2010-04-19
WO2007007129A3 (en) 2007-05-31
CA2613991C (en) 2017-03-07
EP1902319A2 (en) 2008-03-26
EP1902319B1 (en) 2010-01-20
AU2006268034B2 (en) 2012-02-02
CA2613991A1 (en) 2007-01-18
JP2009501333A (ja) 2009-01-15
US20080220013A1 (en) 2008-09-11
GB0514435D0 (en) 2005-08-17
US9028825B2 (en) 2015-05-12
JP5281397B2 (ja) 2013-09-04
AU2006268034A1 (en) 2007-01-18
JP2013092538A (ja) 2013-05-16
DE602006011896D1 (de) 2010-03-11
ATE456055T1 (de) 2010-02-15

Similar Documents

Publication Publication Date Title
GB2428240A (en) Diagnostic method for brain damage-related disorders
CA2532130C (en) Diagnostic method for brain damage-related disorders
Fujii et al. Autoantibodies against the amino terminal of α-enolase are a useful diagnostic marker of Hashimoto's encephalopathy
DK2389587T3 (en) Diagnostic and prognostic methods related Alzheimer's Disease
US20090275046A1 (en) Complement factor H protein as a biomarker of Parkinson's disease
van Beers et al. Mapping of citrullinated fibrinogen B-cell epitopes in rheumatoid arthritis by imaging surface plasmon resonance
JP2018510343A (ja) アルツハイマー病の診断及び治療のための材料及び方法
Haskins et al. Rapid discovery of putative protein biomarkers of traumatic brain injury by SDS–PAGE–capillary liquid chromatography–tandem mass spectrometry
CA2800038A1 (en) Diagnostic methods
CA2932077C (en) Diagnostic method for brain damage-related disorders
JP2009052933A (ja) プリオン病の検出方法及び診断キット

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)